OakChart

SeaStar Medical Holding Corp

ICUHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.92+0.02 (1.05%)
2026-11-11 22:53 CET
Market cap
10.10 USD m
Revenue, TTM
1.71 USD m
Net income, TTM
-13.63 USD m
Free cash flow, TTM
-13.69 USD m
EPS diluted, TTM
-3.93
P/E
-
Compare

Price

ICU against its 20, 50 and 200-day averages
2050200beatmissearnings
2.003.004.005.001.1M2.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ICUclose 1.9220-day 2.4250-day 3.01200-day 3.311.9252w high

64.3% under the 52-week high of 5.38 on 2 Jul 2026. 52-week low 1.84 on 9 Nov 2026. Last 15 sessions, 85.3% high to low

Volume 0.91× normal · the line is the 50-bar volume average

Profile

ICU
52-week range, 2% of the way up
1.845.38

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company was founded on June 6, 2007 and is headquartered in Denver, CO.

Employees17
IPOMar 18, 2021
Beta-1.03
ATR, 14d0.26
Rel volume0.91
Short float3.40%
Insider own3.10%
Inst own4.49%

Snapshot

6 groups

Valuation

Index-
Market Cap10.21M
Enterprise Value3.38M
Income-13.63M
Sales1.71M
Book/sh1.01
Cash/sh1.31
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees17
IPOMar 18, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S5.97
P/B1.90
P/C1.47
P/FCF-
EV/EBITDA-
EV/Sales1.97
Quick Ratio1.87
Current Ratio1.89
Debt/Eq0.03
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-3.93
EPS next Y-2.09
EPS next Q-0.95
EPS this Y37.54%
EPS next Y42.90%
EPS next 5Y49.38%
EPS past 3/5Y74.91% -125.73%
Sales past 3/5Y- -
EPS Y/Y TTM83.96%
Sales Y/Y TTM123.63%
EPS Q/Q48.32%
Sales Q/Q81.95%
EarningsNov 11 AMC
EPS/Sales Surpr.6.19% 26.41%

Ownership

Insider Own3.10%
Insider Trans0.46%
Inst Own4.49%
Inst Trans1.15%
ROA-160.02%
ROE-356.87%
ROIC-317.20%
Gross Margin92.64%
Oper. Margin-816.64%
Profit Margin-795.50%
SMA20-20.63%
SMA50-36.18%
SMA200-41.94%
Trades-

Technical

Shs Outstand5.32M
Shs Float5.15M
Short Float3.40%
Short Ratio1.11
Short Interest0.18M
52W High5.38 -64.31%
52W Low1.84 4.35%
Volatility6.41% 10.91%
ATR (14)0.26
RSI (14)33.31
Beta-1.03
Rel Volume0.91
Avg Volume157.59K
Volume143,208

Performance

Perf Week-5.88%
Perf Month-46.52%
Perf Quarter-39.43%
Perf Half Y-58.26%
Perf YTD-20.00%
Perf Year-60.82%
Perf 3Y-98.65%
Perf 5Y-99.92%
Perf 10Y-
Recom1.00
Target Price12.00
Prev Close1.90
Price1.92
Change %1.05%

Peers

Mkt cap
TickerCompanyMkt cap
CTSOCytosorbents Corp16.83M
CALCCalciMedica Inc8.46M
AEMDAethlon Medical Inc8.87M
NUWENuwellis Inc2.99M
OMOutset Medical Inc78.61M
UNCYUnicycive Therapeutics Inc105.29M
PROKProKidney Corp341.68M
BAXBaxter International Inc13.63B
FMSFresenius Medical Care AG ADR11.53B
XAIRBeyond Air Inc4.38M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Messinger MichaelChief Financial OfficerAug 18 '26Buy3.277502,4522,500Aug 19 04:21 PM
Baird Jennifer ADirectorDec 19 '25Buy0.244,20098736,200Dec 22 06:55 PM
Messinger MichaelChief Financial OfficerDec 09 '25Buy0.3514,5005,09817,500Dec 11 06:49 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 665.71M
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B

News

latest 14 of 100
  • SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • SeaStar Medical's Quell Immune Growth Faces A Cash And Enrollment Test This Quarter (Earnings Whispers) -5.88%
  • SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026 (GlobeNewswire)
  • FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients (GlobeNewswire) -8.68%
  • SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE SAVE Registry Analysis in Pediatric Sepsis-Associated AKI (GlobeNewswire) -10.09%
  • SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award (GlobeNewswire) -16.16%
  • FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition (GlobeNewswire) +16.61%
  • SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds (GlobeNewswire) -24.31%
  • SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026 (GlobeNewswire) +25.07%
  • New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical's SCD Therapy for Acute Kidney Injury (AKI) (GlobeNewswire)
  • SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026 (GlobeNewswire)
  • SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy (GlobeNewswire)
  • SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • SeaStar Medical Holding Corp (ICU) (Q2 2026) Earnings Call Highlights: Qualimmune Revenue ... (GuruFocus.com) -5.65%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-11--0.950--0.501
2026Q22026-08-12-0.910-0.970-0.9100.620.492
2026Q12026-05-13-0.900-0.825-0.8990.500.442
2025Q42026-03-25-0.800-1.080-0.8020.420.222
2025Q32025-11-13-1.300-1.500-1.3160.180.251
2025Q22025-08-13-1.800-4.300-1.7670.340.201
2025Q12025-05-14-4.400-5.200-4.3770.290.151
2024Q42025-03-27-9.000-8.900-7.3930.070.151
2024Q32024-11-13-11.000-11.300-10.9570.070.081
2024Q22024-08-13-10.300-14.100-10.2570.000.001
2024Q12024-05-14-47.500--47.3030.00--
2023Q42024-04-18-47.500-32.500-51.848--1
2023Q32023-11-14-92.500-62.500-92.600--1
2023Q22023-08-14-62.500-62.500-61.425--1
2023Q12023-05-15-100-50.000-100.99--1
2022Q42023-04-19-585--511.08---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-700--371.14--
2023FY-302.5-287.5-302.63--
2024FY-66.300-77.500-66.3270.140.22
2025FY-5.860-6.400-5.8601.231.03
2026FY--3.660--2.00
2027FY--2.090--3.00
2028FY--0.760--16.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-221000.500.500.50
2026Q3S2026-08-132000.450.400.50
2026Q3S2026-08-122000.450.400.50
2026Q3S2026-07-282000.450.400.50
2026Q3S2026-05-142100.450.400.50
2026Q3S2026-04-012000.430.350.50
2026Q3S2026-03-261000.350.350.35
2026Q3S2026-01-281000.350.350.35
2026Q3S2025-11-141010.350.350.35
2026Q3S2025-11-111010.540.540.54
2026Q3S2025-11-101010.540.540.54
2026Q3S2025-11-091010.540.540.54
2026Q3S2025-11-081010.540.540.54
2026Q3S2025-11-071010.540.540.54

Estimate history

EPS, annual-0.1-88.108-371.138-302.625-66.327-5.861-3.9292
Period202020212022202320242025TTM
EPS, quarterly-10.257-10.957-7.393-4.377-1.767-1.316-0.802-0.899-0.913
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000.1351.2341.71
Period202020212022202320242025TTM
Sales, quarterly00.0680.0670.2930.3380.1830.420.4950.615
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0520.0520.0510.190.5983.8454.26
Period202020212022202320242025MRQ
Shares, quarterly0.3220.4210.5980.9261.7343.413.8453.9944.26
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue1.711.230.140.000.000.000.00
Cost of Goods Sold Incl. D&A0.130.05-0.000.000.000.00
Gross Profit1.591.18-0.000.000.000.00
Selling, General and Administrative Excl. Other15.5813.3617.9814.219.424.450.01
Research and Development8.917.529.115.972.502.77-
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-13.99-12.18-17.84-14.21-9.42-4.45-0.01
Interest Expense0.030.330.241.080.630.21-
Unusual Expense0.00-0.036.849.78-8.070.030.00
Net Income Before Taxes-13.62-12.15-24.83-26.23-12.19-4.60-0.01
Income Taxes0.000.000.000.000.00-0.000.00
Consolidated Net Income-13.63-12.15-24.83-26.23-12.19-4.60-0.01
Net Income From Continuing Operations-13.63-12.15-24.83-26.23-12.19-4.60-0.01
Net Income-13.63-12.15-24.83-26.23-12.19-4.60-0.01
EPS (Recurring)-3.34-5.87-53.53-223.61-543.15-87.74-0.10
EPS (Basic, Before Extraordinaries)-3.93-5.86-66.33-302.62-371.14-88.11-0.10
EPS (Diluted)-3.93-5.86-66.33-302.62-371.14-88.11-0.10
EBITDA-13.99-12.18-17.84-14.21-9.42-4.45-0.01
Non-Operating Income (Expense)0.390.330.10-1.16-10.210.090.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense0.320.490.811.931.04--
Price To Earnings Ratio----17.4517.45-
Price To Sales Ratio8.754.0353.80----
Gross Margin92.6495.71-----
Operating Margin-816.64-986.63-13,216.30----
Net Margin-795.50-984.60-18,392.59----
Shares Outstanding4.263.840.600.190.050.050.05
Market Capitalization10.1010.1011.6012.0453.4753.47-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.610.490.420.180.340.290.070.07
Cost of Goods Sold Incl. D&A0.050.050.010.010.03---
Gross Profit0.560.450.410.170.31---
Selling, General and Administrative Excl. Other4.354.053.423.752.074.124.834.52
Research and Development2.522.342.201.851.042.432.742.34
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.79-3.60-3.02-3.58-1.76-3.82-4.77-4.46
Interest Expense0.010.010.010.000.310.01-0.27
Unusual Expense0.000.000.000.00-0.02-0.02-0.08-0.19
Net Income Before Taxes-3.73-3.52-2.90-3.47-2.00-3.77-4.42-4.48
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.73-3.52-2.90-3.47-2.00-3.77-4.42-4.48
Net Income From Continuing Operations-3.73-3.52-2.90-3.47-2.00-3.77-4.42-4.48
Net Income-3.73-3.52-2.90-3.47-2.00-3.77-4.42-4.48
EPS (Recurring)-0.91-0.90-0.80-1.32-1.78-4.39-7.48-11.29
EPS (Basic, Before Extraordinaries)-0.91-0.90-0.80-1.32-1.77-4.38-7.39-10.96
EPS (Diluted)-0.91-0.90-0.80-1.32-1.77-4.38-7.39-10.96
EBITDA-3.79-3.60-3.02-3.58-1.76-3.82-4.77-4.46
Non-Operating Income (Expense)0.070.090.120.110.040.050.270.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.100.070.060.290.100.170.280.20
Price To Sales Ratio8.7510.157.0417.086.3033.4285.90256.03
Gross Margin91.2290.7197.1492.3592.01---
Operating Margin-616.42-727.88-718.10-1,955.74-519.53-1,304.44-7,114.93-6,552.94
Net Margin-606.50-711.31-691.43-1,897.27-592.31-1,287.37-6,595.52-6,585.29
Shares Outstanding4.263.993.843.411.730.930.600.42
Market Capitalization10.1014.869.2319.437.3815.3711.6017.95

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments11.981.820.180.050.510.04
Short Term Receivables0.240.110.000.010.060.00
Inventories0.070.000.000.000.000.00
Other Current Assets1.301.832.131.460.030.00
Total Current Assets13.583.772.311.520.600.04
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets----0.000.00
Other Assets0.580.891.211.520.000.23
Total Assets14.164.663.513.040.600.27
Short Term Debt Incl. Current Port. of LT Debt0.530.574.741.182.850.13
Accounts Payable0.953.050.000.000.000.00
Other Current Liabilities2.273.228.3014.970.270.12
Total Current Liabilities3.746.8413.0516.153.120.25
Long Term Debt0.000.004.347.650.300.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.746.8417.3823.803.420.25
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity10.42-2.18-13.87-20.76-2.820.02
Total Shareholders Equity10.42-2.18-13.87-20.76-2.820.02
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity10.42-2.18-13.87-20.76-2.820.02
Total Liabilities & Stockholders Equity14.164.663.513.040.600.27
Book Value Per Share2.71-3.65-72.82-408.71-53.980.38
Tangible Book Value Per Share2.71-3.65-72.82-408.71-53.980.38
Full-Time Employees171912922
Price to Book Ratio1.88-5.31-0.760.550.55-
Return on Assets-129.15-607.76-633.62-669.60-1,053.88-
Return on Equity-295.15---53.040.16-
Return on Invested Capital-116.65-----26.49
Quick Ratio3.610.550.180.090.190.15
Current Ratio3.630.550.180.090.190.15

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-13.63-12.15-24.83-26.23-12.19-4.60-0.01
Other Funds (Non Cash)0.370.917.8313.071.840.160.00
Funds from Operations-13.26-11.24-17.00-13.16-10.35-4.43-0.01
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-0.43-2.360.992.882.55-0.68-0.11
Cash from Operating Activities-13.69-13.60-16.01-10.29-7.79-5.11-0.11
Capital Expenditures0.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.00-105.570.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock14.2323.8322.065.518.750.000.03
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock14.2323.8322.065.518.750.000.03
Proceedsfrom Stock Options18.0022.0117.444.928.750.000.03
Issuance or Reduction of Debt, Net0.12-0.07-4.413.03-1.462.820.13
Change in Long Term Debt0.12-0.07-4.413.03-1.462.820.00
Issuance of Long Term Debt0.770.771.698.8010.562.840.00
Reduction of Long Term Debt-0.65-0.83-6.10-5.77-12.02-0.020.00
Net Financing Active Other Cash Flow0.000.000.001.870.040.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.00
Cash from Financing Activities14.3523.7617.6510.417.332.820.15
Net Change in Cash0.6610.161.640.13-0.46-2.300.04
Free Cash Flow-13.69-13.60-16.01-10.29-7.79-5.11-0.11
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments6.969.3511.9813.766.305.30
Short Term Receivables0.210.180.240.220.220.11
Inventories0.080.060.070.080.080.04
Other Current Assets0.981.181.300.811.051.33
Total Current Assets8.2310.7613.5814.877.656.78
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.420.500.580.660.740.81
Total Assets8.6511.2614.1615.538.387.60
Short Term Debt Incl. Current Port. of LT Debt0.130.330.530.000.000.36
Accounts Payable0.750.720.952.023.163.40
Other Current Liabilities3.472.902.272.051.883.27
Total Current Liabilities4.353.953.744.075.047.03
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities4.353.953.744.075.047.03
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.307.3210.4211.463.340.56
Total Shareholders Equity4.307.3210.4211.463.340.56
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.307.3210.4211.463.340.56
Total Liabilities & Stockholders Equity8.6511.2614.1615.538.387.60
Book Value Per Share1.011.832.713.361.930.61
Tangible Book Value Per Share1.011.832.713.361.930.61
Full-Time Employees181717171819
Price to Book Ratio1.881.370.891.702.2127.20
Return on Assets-160.02-126.18-129.15-135.86-247.61-207.41
Return on Equity-356.87-302.01-295.15-290.37--
Return on Invested Capital-86.82-48.13-27.88-30.29-59.92-667.61
Quick Ratio1.872.713.613.641.500.96
Current Ratio1.892.733.633.661.520.96

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.73-3.52-2.90-3.47-2.00-3.77
Other Funds (Non Cash)-0.090.100.070.290.390.16
Funds from Operations-3.82-3.42-2.83-3.18-1.62-3.61
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.830.66-1.26-0.66-1.390.96
Cash from Operating Activities-2.99-2.76-4.09-3.84-3.01-2.65
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.810.331.7911.304.386.35
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.810.331.7911.304.386.35
Proceedsfrom Stock Options0.810.337.679.183.591.57
Issuance or Reduction of Debt, Net-0.20-0.200.530.00-0.37-0.22
Change in Long Term Debt-0.20-0.200.530.00-0.37-0.22
Issuance of Long Term Debt0.000.000.770.000.000.00
Reduction of Long Term Debt-0.20-0.20-0.240.00-0.37-0.22
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.600.132.3111.304.016.13
Net Change in Cash-2.39-2.63-1.787.461.013.48
Free Cash Flow-2.99-2.76-4.09-3.84-3.01-2.65

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 135.00K 2025: 1.23M
United States2024: 135.00K 2025: 1.23M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.40%0.2M5.2M123.72K
2026-10-154.35%0.2M4.3M111.09K
2026-09-303.37%0.1M4.3M72.70K
2026-09-152.85%0.1M4.3M77.84K
2026-08-312.60%0.1M4.3M87.37K
2026-08-142.86%0.1M4.3M91.24K
2026-07-312.36%0.1M3.9M91.17K
2026-07-153.60%0.1M3.9M96.93K
2026-06-302.12%0.1M3.9M107.48K
2026-06-153.27%0.1M4.0M145.57K
2026-05-293.57%0.1M4.0M139.12K
2026-05-153.98%0.2M3.9M136.41K
2026-04-305.60%0.2M3.9M141.14K
2026-04-154.10%0.2M3.9M145.43K
2026-03-315.53%0.2M3.9M147.34K
2026-03-134.54%0.2M3.7M108.37K
2026-02-276.30%0.2M3.7M127.44K
2026-02-137.74%0.3M3.7M198.63K
2026-01-304.10%0.2M3.8M192.12K
2026-01-153.62%0.1M3.8M190.08K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-11-038-KCurrent report2026-10-30SEC
2026-10-30S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-08DNotice of sales of securities on Form D (Regulation D)SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-21S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-018-KCurrent report2026-06-25SEC
2026-06-238-K/A2025-08-13SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-13424B3SEC
2026-05-13SCHEDULE 13G/ASEC
2026-05-11EFFECTEffectiveness filing by commission orderSEC
2026-05-11SCHEDULE 13GSEC
2026-05-08CORRESPSEC
2026-05-07S-1/ASEC
2026-05-05EFFECTEffectiveness filing by commission orderSEC
2026-05-05EFFECTEffectiveness filing by commission orderSEC
2026-05-05EFFECTEffectiveness filing by commission orderSEC
2026-05-05UPLOADUpload SubmissionSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-082.45K100
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-126.09K200
2025-110000

Institutional holders

Manager% owned
LPL Financial LLC1.52%
GEODE CAPITAL MANAGEMENT, LLC1.16%
VANGUARD CAPITAL MANAGEMENT LLC0.83%
UBS Group AG0.60%
VANGUARD FIDUCIARY TRUST CO0.34%
JANE STREET GROUP, LLC0.32%
NORTHERN TRUST CORP0.26%
PNC FINANCIAL SERVICES GROUP, INC.0.11%
Tower Research Capital LLC0.03%
BlackRock, Inc.0.02%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.83%
Fidelity Extended Market Index Fund0.47%
Fidelity Total Market Index Fund0.20%
Fidelity Nasdaq Composite Index Fund0.16%
Fidelity Series Total Market Index Fund0.13%
Dimensional U.S. Core Equity 2 ETF0.07%
Blackstone Alternative Multi-Strategy Fund-0.02%

OakChart. ICU. Cached 15 minutes.

Some panels did not load: ratings.